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Smooth muscle cell migration and
proliferation are mediated by distinct
phases of activation of the intracellular
messenger mitogen-activated protein
kinase
Peter R. Nelson, MD, Shinji Yamamura, MD, Leila Mureebe, MD, Hiroyuki
Itoh, MD, PhD, and K. Craig Kent, MD, FACS, Boston, Mass.
Purpose: Mitogen-activated protein kinase (MAPK) is a ubiquitous signaling protein that
has been associated with cellular proliferation; however, its role in cellular migration has
not been established. In this study, we investigate the role of MAPK in platelet-derived
growth factor (PDGF)–induced migration and proliferation of human vascular smooth
muscle cells (SMCs).
Methods: SMC migration was measured using a microchemotaxis assay (4 hours), and
proliferation was assessed using 3H-thymidine uptake and cell counts. PD098059 was
used as a specific noncompetitive inhibitor of MAPK activation.
Results: Coincubation of SMCs with PD098059 resulted in significant inhibition of
PDGF-BB (5 ng/ml)–induced SMC chemotaxis and proliferation. The IC50 for both
processes was approximately 10 mmol/L with complete inhibition at 50 mmol/L.
Stimulation of SMCs with PDGF produced an early peak in MAPK activity followed by
a plateau of activity that persisted for 24 hours. We hypothesized that variations in the
temporal activation of MAPK might explain the action of this enzyme on these two dis-
parate cellular events. By adding PD098059 at intervals after stimulation of SMCs with
PDGF, we demonstrated an association between MAPK activity within the first 15 min-
utes and SMC migration, whereas MAPK activity between 1 and 4 hours was associat-
ed with SMC proliferation.
Conclusions: MAPK activity is essential for both SMC migration and proliferation, and
distinct phases of enzyme activation are required to stimulate these two discrete cellular
events. Inhibition of this signaling protein may prove to be a useful method for pre-
venting intimal hyperplasia. (J Vasc Surg 1998;27:117-25.)
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The success of vascular reconstruction remains
limited by restenosis that develops as a result of inti-
mal hyperplasia. Vascular smooth muscle cell (SMC)
migration and proliferation are both necessary
events that contribute to the formation of intimal
plaque.1 SMCs at sites of arterial injury are exposed
to and influenced by a number of growth factors,
extracellular matrix proteins, and cytokines that
mediate these pathologic processes.2 In some
instances, the same factor can stimulate both migra-
tion and proliferation, the predominant example
being the potent agonist platelet-derived growth
factor (PDGF).
Strategies to inhibit the formation of intimal
hyperplasia include the use of agents that alter either
the extracellular or intracellular events responsible
for the pathologic behavior of SMCs. Success with
the latter approach requires an understanding of the
intracellular signaling pathways that mediate SMC
migration and proliferation. The ultimate cellular
events that are required for these two processes are
distinct; migration requires cytoskeletal mobiliza-
tion, and proliferation is dependent on nuclear acti-
vation. However, in the case of PDGF, there must
be an initial common signaling pathway that at some
level diverges into pathways that are specific for each
process. Second messenger proteins that are specific
for migration or proliferation have been identified;
however, the precise point of divergence is not
known.
Mitogen-activated protein kinase (MAPK) is a
ubiquitous intracellular serine-threonine kinase that
plays a fundamental role in many cellular processes.
A variety of MAPK isotypes have been isolated; how-
ever, the most widely studied are the 44 and 42 kd
proteins designated as extracellular signal-regulated
protein kinases (ERK), ERK-1 and ERK-2, respec-
tively. MAPK activity is stimulated by a number of
growth factors, differentiating agents, cytokines, and
vasoactive substances, and a wide range of substrates
for MAPK have been identified.3
We and others have demonstrated that multiple
growth factors, including PDGF-BB, activate
MAPK in human vascular SMCs.4 Using an assay of
MAPK activity, we found that PDGF-BB activated
MAPK for an interval up to 24 hours, with an initial
peak in activity at 10 minutes, followed by a plateau
of approximately 45% of this peak that persisted for
the remainder of the 24-hour period. We have also
demonstrated an association between MAPK activa-
tion and SMC proliferation.4,5 For both basic
fibroblast growth factor (bFGF) and PDGF, there
was a precise correlation between the ability of these
agonists to activate MAPK and their potential to
induce a proliferative response. However, a direct
cause/effect relationship between MAPK activation
and SMC proliferation has not been definitively
established.
The role of MAPK in cellular migration is less
well understood. Bornfeldt et al.6 hypothesized that
MAPK is not necessary for SMC migration. They
found PDGF to be both a potent stimulus of MAPK
activity and a strong agonist of SMC chemotaxis.
However, insulin-like growth factor I, which was
also a potent agonist of SMC migration, stimulated
very little MAPK activity. Recent reports have
addressed the importance of MAPK in migration of
other cell types. Klemke et al.7 found that MAPK is
necessary for migration of a carcinoma cell line,
whereas Sa and coworkers8 have implicated MAPK
signaling in endothelial cell motility. In contrast,
Knall et al.9 revealed that MAPK is not necessary for
migration of neutrophils.
PD098059 is a selective, noncompetitive,
reversible inhibitor of the MAPK signaling pathway
characterized by Alessi and collaborators.10 This
inhibitor, which is cell-permeable, blocks the activa-
tion of MAPK by MAPK kinase (MAPKK) and has
been used to define the role of MAPK in intracellu-
lar signaling responses to nerve growth factor,
insulin, and growth hormone. In concentrations less
than 100 mmol/L, PD098059 does not appear to
effect other intracellular pathways, including raf,
protein kinase C, phospholipase C, phosphatidyl-
inositol 3-kinase, cyclic adenosine monophos-
phate–dependent kinase, v-Src, p70 S6 kinase, and
the epidermal growth factor (EGF) and PDGF
receptor kinases.11-14 Moreover, PD098059 is also
selective for ERK-1 and ERK-2 and has no effect on
other MAPK isotypes, including p38/reactivating
kinase (p38/RK) and p54 stress-activated protein
kinase/c-Jun N-terminal kinase (SAPK/JNK).15
Using this inhibitor, we explored the role of
MAPK in migration and proliferation of human vas-
cular SMCs. We found that MAPK is required for
both processes. Moreover, our data suggest that dis-
tinct phases of MAPK activation are required to
stimulate these two discrete cellular events.
METHODS
Materials
Human recombinant PDGF-BB was obtained
from Upstate Biotechnologies, Inc. (Lake Placid,
N.Y.). The MAPKK inhibitor PD098059 (2-(2-
amino-3-methoxyphenyl)-4H-1-benzopyran-4-one)
was obtained from Research Biochemicals
International (Natick, Mass.). Dulbecco’s modified
Eagle’s medium (DMEM), phosphate-buffered
saline solution (PBS), fetal bovine serum,
trypsin–ethylenediamine tetraacetic acid (EDTA),
penicillin/streptomycin/Fungizone solution, and
N-2-hydroxyethylpiperazine-N-2-ethanesulfonic
acid (HEPES) were obtained from Gibco BRL Life
Technologies (Gaithersburg, Md.). L-glutamine was
obtained from BioWhitaker (Walkersville, Md.).
[Methyl-3H] thymidine and g-32P-ATP (6000
Ci/mmol) were obtained from DuPont New
England Nuclear (Boston, Mass.). Rabbit antirat
ERK-2 MAPK antibody, which has substantial cross-
reactivity to human and other species, was obtained
from Santa Cruz Biotechnology (Santa Cruz,
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Calif.). Polycarbonate 8 mm-pore membranes were
obtained from Poretics Corp. (Livermore, Calif.).
Rabbit brain myelin basic protein, adenosine 5’-
triphosphate (ATP, disodium salt), the smooth mus-
cle–specific actin immunostaining kit, and other
stock chemicals were purchased from Sigma
Chemical Company (St. Louis, Mo.). Protein A-
sepharose was obtained from Pharmacia Biotech
(Uppsala, Sweden).
Cell culture
Human SMCs were explanted from saphenous
vein harvested at the time of aortocoronary or
peripheral arterial bypass grafting, as previously
described.16 Endothelial and adventitial layers were
gently removed from segments of vein, and frag-
ments of the medial layer were placed onto tissue
culture plates. Outward-growing SMCs were har-
vested and subcultured in DMEM supplemented
with 10% fetal bovine serum, 25 mmol/L HEPES,
40 U/ml penicillin G, 40 mg/ml streptomycin, 100
ng/ml amphotericin B, and 4.8 mmol/L L-gluta-
mine at 37° C and 5% CO2 in room air. Cells in pas-
sages 1 through 5 were used for all experimentation.
SMC identity was verified by immunostaining with
antihuman a-actin antibody and by a characteristic
hill-and-valley growth pattern.
Migration assay
SMCs were grown to confluence and then made
quiescent in serum-free DMEM for 72 hours. Cells
were washed in PBS, harvested using 0.05% trypsin-
EDTA, and resuspended in serum-free DMEM.
Migration was assayed for 4 hours at 37° C in a 48-
well microchemotaxis chamber (Neuroprobe, Cabin
John, Md.) with upper and lower wells separated by
a polycarbonate 8 mm-pore membrane. For all
assays, SMCs in the presence or absence of
PD098059 were seeded at a density of 50,000 per
well (6000/mm2) into the upper well of the cham-
ber. PDGF-BB diluted in DMEM was added to the
lower well. Vehicle in DMEM served as a control.
After completing the assay, the membrane was
washed in PBS, fixed in 70% ethanol for 20 minutes
at –20° C, and stained in hematoxylin overnight.
The upper side of the membrane was carefully
scraped using a cotton swab, leaving the cells that
had migrated to the lower surface undisturbed. The
membrane was then mounted onto a microscope
slide, and migration in each well was assessed with
light microscopy by counting the number of cells in
five independent, random, high-power fields at
200´ magnification.
Attachment assay
Attachment assays were performed for 2 hours at
37° C in a 48-well microchemotaxis chamber. For all
assays, SMCs in serum-free DMEM were seeded at
a density of 2000 cells per well (240/mm2) into the
upper well of the chamber. Cells in the presence or
absence of the inhibitor PD098059 were added to
the upper well of the chamber, and after a 2-hour
period the membranes were washed in PBS, fixed in
ethanol, and stained in hematoxylin as described for
the migration assay. Attachment to both the upper
and lower surfaces of the membrane was assessed
with light microscopy at 200´ magnification by
counting the total number of cells on both sides of
the membrane.
Proliferation assay
DNA synthesis. SMCs were seeded into a 24-
well plate at a concentration of 104 cells/well and
were allowed to attach overnight. These cells were
starved in serum-free DMEM for 72 hours and then
stimulated for 24 hours with PDGF-BB (5 ng/ml)
in the presence or absence of PD098059. During
the final 4 hours of the assay, 2 mCi of [methyl-3H]-
thymidine was added to each well. Cells were then
rinsed with PBS and treated with 10% (w/w)
trichloroacetic acid. After washing with 95% ethanol,
the trichloroacetic acid–insoluble fraction was solu-
bilized with 0.5 N NaOH, and radioactivity was
measured using a scintillation counter.
Cell counts. SMCs were seeded at a concentra-
tion of 3 ´ 104 cells/well in six-well plates and were
allowed to attach overnight. Cells were then starved
in serum-free DMEM for 72 hours and were incu-
bated for an additional 72 hours in DMEM contain-
ing PDGF-BB (5 ng/ml) in the presence or absence
of PD098059. At the end of the 72-hour incuba-
tion, cells were removed with trypsin-EDTA and
quantified with a Coulter Counter (Coulter
Electronics, Hialeah, Fla.).
MAPK immunoprecipitation/activity assay
SMCs were allowed to grow to confluence in 75
cm2 plates and were rendered quiescent in serum-
free DMEM for 72 hours. After stimulation with
PDGF, in the presence or absence of PD098059,
SMCs were lysed with radioimmunoprecipitation
assay (RIPA) buffer (10 mmol/L Tris-HCl, pH 7.5,
1.0% Triton X-100, 0.5% NP 40, 150 mmol/L
NaCl, 50 mmol/L NaF, 0.5 mmol/L Na ortho-
vanadate, 1.0 mmol/L EGTA, 1.0 mmol/L EDTA,
0.5 mmol/L phenylmethylsulfonyl fluoride) for 20
minutes on ice. Cell lysates were collected into
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microcentrifuge tubes, vortexed, and centrifuged at
4° C for 20 minutes. Protein concentration was
measured in the supernatant and equalized for all
samples. Cell lysates were then coincubated with
rabbit antirat ERK-2 MAPK antibody at a concen-
tration of 2 mg/ml for 2 hours. The antibody-
MAPK complex was then conjugated to protein A-
sepharose overnight, centrifuged, and washed three
times in RIPA buffer and twice in RIPA containing
500 mmol/L NaCl. The immunoprecipitated pellet
was resuspended in an equal volume of kinase buffer
containing 10 mmol/L Tris-HCl, pH 7.5, 150
mmol/L NaCl, 10 mmol/L MgCl2, for a final vol-
ume of 50 ml. Five mCi of g-32P-ATP, 8 mg myelin
basic protein, and 10 mmol/L ATP were added to
each sample. The reaction was allowed to continue
for 30 minutes at 30° C and was then halted by the
addition of 4x Laemmli buffer (250 mmol/L Tris-
HCl, pH 6.8, 8% sodium dodecylsulfate [SDS], 20%
glycerol, 10% 2-mercaptoethanol). Samples were
then boiled for 5 minutes, quenched on ice for an
additional 5 minutes, and then subjected to sodium
dodecylsulfate–polyacrylamide gel electrophoresis
(SDS-PAGE). Dried gels were analyzed by autoradi-
ography.
Isolation of temporal phases of MAPK activation
To temporally isolate MAPK activity, PD098059
(50 mmol/L) was added coincident with and at
intervals after PDGF stimulation. For example, the
addition of this inhibitor at a point 15 minutes after
stimulation of SMCs with PDGF allowed the occur-
rence of the first 15 minutes of MAPK activation
(i.e., the early peak) but eliminated all subsequent
activity (i.e., the plateau phase). Thus the migratory
or proliferative response of SMCs subjected to these
circumstances was related only to the MAPK activi-
ty that occurred during this initial 15-minute period.
Longer and shorter periods of MAPK activation
were isolated by adding the inhibitor at earlier or
later time intervals.
Statistical analysis
Statistical comparisons were made using an
unpaired Student’s t test with Statview (BrainPower
Inc., Calabasas, Calif.) software on a Macintosh
System (Apple Computer, Inc., Cupertino, Calif.).
For all comparisons, a p value less than 0.05 was
considered significant. The reported results are a
representative example from one cell line; however,
we confirmed these results using cells from at least
three different donors.
RESULTS
MAPK activation by PDGF-BB in SMCs is
inhibited by PD098059. To evaluate whether the
inhibitor, PD098059, could block MAPK activity in
intact human vascular SMCs, we measured MAPK in
quiescent SMCs 10 minutes subsequent to their
simultaneous stimulation with PDGF-BB (5 ng/ml)
and increasing concentrations of PD098059.
PD098059, in concentrations ranging from 0.1 to
1.0 mmol/L, had no effect on MAPK activity,
whereas 10 mmol/L partially eliminated and 50
mmol/L completely eliminated the increase in
MAPK activity produced by PDGF (Fig. 1). Thus
PD098059 was an immediate and effective inhibitor
of PDGF-induced MAPK activation. We then evalu-
ated whether PD098059 (50 mmol/L), when added
to SMCs in a delayed fashion after PDGF stimula-
tion, eliminated all subsequent MAPK activity.
PD098059 was added at intervals after stimulation
of SMCs with PDGF, and MAPK activity was mea-
sured 5 minutes subsequent to the addition of the
inhibitor. When added at time points ranging from
5 minutes to 4 hours after stimulation of SMCs with
PDGF, PD098059 consistently eliminated all subse-
quent MAPK activity (data not shown).
MAPK activation is necessary for SMC
chemotaxis. To determine whether MAPK activa-
tion is necessary for SMC migration, chemotaxis to
PDGF was measured in the presence of increasing
concentrations of PD098059. PDGF-BB alone (5
ng/ml) consistently produced a 3.5- to 4.5-fold
increase in SMC chemotaxis as measured using a 4-
hour microchemotaxis chamber assay. The concen-
trations of PD098059 required to inhibit chemo-
taxis were similar to those required to inhibit MAPK
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Fig. 1. Effect of PD098059 on PDGF-BB–induced acti-
vation of MAPK. Quiescent SMCs were simultaneously
incubated with varying concentrations of PD098059 and
PDGF-BB (5 ng/ml) for 10 minutes. MAPK activity, as
measured by phosphorylation of its substrate myelin basic
protein, was determined using immunoprecipitation and
SDS-PAGE techniques as described in Methods. This
experiment was repeated three times using cells derived
from different saphenous veins. A representative example
is displayed.
activity. Low concentrations of PD098059 (0.1 to 1
mmol/L) had no effect on chemotaxis, whereas 10
mmol/L partially inhibited (~80%) and 50 mmol/L
completely inhibited the chemotactic effect of
PDGF (Fig. 2). The IC50 for the inhibitory effect of
PD098059 on PDGF-induced SMC chemotaxis was
8 mmol/L. In separate assays, PD098059 had no
effect on SMC attachment (data not shown). Thus
the diminished chemotaxis that we observed in these
assays was not the result of an effect of PD098059
on attachment of SMCs to the polycarbonate mem-
branes of the microchemotaxis chambers.
MAPK activation is necessary for SMC pro-
liferation. Our previous studies have suggested a
positive association between MAPK activation and
SMC proliferation.4,5 To verify a causal relationship
between these two events, DNA synthesis (3H-
thymidine incorporation) was measured in SMCs
stimulated with PDGF-BB (5 ng/ml) coincubated
with increasing concentrations of PD098059.
PDGF produced a sixfold increase in DNA synthesis
that was inhibited by PD098059 in a concentration-
dependent fashion (Fig. 3, A). The IC50 for the
effect was 10 mmol/L, and there was complete inhi-
bition of proliferation with a PD098059 concentra-
tion of 50 mmol/L. PD098059, in similar concen-
trations, inhibited the stimulatory effect of PDGF
on SMC proliferation as measured by cell counts
(Fig. 3, B). Thus activation of MAPK is clearly nec-
essary for PDGF-induced SMC proliferation.
Chemotaxis requires early activation, and
proliferation requires late activation of MAPK.
Our data suggest that activation of MAPK leads to
two distinct cellular events—migration and prolifer-
ation. In previous studies, we found that stimulation
of SMCs with PDGF resulted in an early peak (10
minutes) followed by a persistent plateau in MAPK
activity.4 It has been postulated that a cascade of
early cellular events results in cell migration.
Conversely, studies in ours and other laboratories
have shown that more delayed processes may be
associated with cellular proliferation.4,17 We, there-
fore, postulated that the initial peak of PDGF-
induced MAPK activity is required for SMC chemo-
taxis and that the later plateau of MAPK activity is
necessary for SMC proliferation.
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Fig. 2. Effect of PD098059 SMC chemotaxis. Quiescent
SMCs were stimulated with PDGF (5 ng/ml) in the pres-
ence of increasing concentrations of PD098059.
Chemotaxis was determined using a 4-hour microchemo-
taxis chamber assay as described in Methods. Results are
expressed as mean percent of control (PDGF-stimulated)
chemotaxis ± SD. All experiments were repeated three
times using cells derived from different saphenous veins. A
representative example is displayed.
Fig. 3. Effect of PD098059 on SMC proliferation.
Quiescent SMCs were stimulated with PDGF (5 ng/ml)
in the presence of increasing concentrations of
PD098059. SMC proliferation was determined by mea-
suring (A) DNA synthesis by 3H-thymidine incorpora-
tion, or (B) cell counts as described in Methods. Results
are expressed as mean percent of control (PDGF-stimulat-
ed) proliferation ± SD. All experiments were repeated
three times using cells derived from different saphenous
veins. A representative example is displayed.
To test the first component of this hypothesis—
that the early peak of MAPK activity is required for
SMC chemotaxis—MAPK was inhibited by adding
PD098059 (50 mmol/L) coincident with and at
varying time points after stimulation of SMCs with
PDGF-BB (Fig. 4, B). As previously demonstrated,
simultaneous exposure of SMCs to PD098059 and
PDGF completely blocked SMC chemotaxis.
Chemotaxis was only partially inhibited if
PD098059 was added 5 minutes after PDGF stimu-
lation, suggesting that MAPK activity within the first
5 minutes is at least in part necessary to produce
chemotaxis. If PD098059 was added at time points
of 15 minutes or later after PDGF stimulation,
chemotaxis was no longer inhibited. These findings
suggest that MAPK activity that occurs greater than
15 minutes after PDGF stimulation is not required
for SMC chemotaxis. Thus only MAPK activity that
occurs within the first 15 minutes after PDGF stim-
ulation is critical for the induction of SMC chemo-
taxis. Because MAPK activity peaks 10 minutes after
stimulation of SMCs with PDGF, it appears that this
early peak is necessary for the migratory effect of
PDGF.
In similar experiments, we analyzed the relation-
ship between the temporal course of MAPK activa-
tion and SMC proliferation. MAPK was inhibited
using PD098059 (50 mmol/L) coincident with and
at varying time points after PDGF stimulation of
DNA synthesis (Fig. 4, A). SMC proliferation was
completely eliminated when PD098059 was added
at time points up to and including 1 hour after stim-
ulation of SMCs with PDGF. Thus the MAPK activ-
ity within the first hour after PDGF stimulation was
not sufficient to produce a proliferative response. If
PD098059 was added at or greater than 4 hours
after PDGF stimulation, proliferation was no longer
inhibited. These findings suggest that MAPK activi-
ty that occurs greater than 4 hours after PDGF stim-
ulation is not required for SMC proliferation. Thus
only MAPK activity that occurs between 1 and 4
hours after PDGF stimulation appears to be required
for the induction of SMC proliferation.
DISCUSSION
Both migration and proliferation of SMCs are
prerequisite for the development of intimal hyper-
plasia, and both processes are simultaneously stimu-
lated by growth factors such as PDGF. However,
both processes are distinct, with migration requiring
recruitment of integrins, focal adhesion proteins,
and actin filaments, and proliferation requiring the
activation of nuclear transcription factors that lead to
the initiation of DNA synthesis. Because PDGF can
stimulate both migration and proliferation, there
must be divergence of the signaling pathway of this
growth factor at some intracellular level beyond the
receptor. The precise point of divergence has not
been well elucidated. However, because MAPK acti-
vation can lead to both migration and proliferation,
the division in the signaling pathways must be distal
to MAPK and its upstream activators.
The selective inhibitor of MAPKK, PD098059,
blocked both SMC migration and proliferation at
concentrations similar to those required for the in
vivo inhibition of MAPK in SMCs and in other cel-
lular systems.10 The finding that MAPK activation
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Fig. 4. Relationship between temporal activation of
MAPK and SMC migration and proliferation. A, DNA
synthesis was measured (as described in Methods) with
PD098059 (50 mmol/L) added either simultaneously or
at intervals after PDGF stimulation (5 ng/ml). Results are
expressed as mean percent of control (PDGF-stimulated)
proliferation ± SD. B, Microchemotaxis assays were per-
formed (as described in Methods) with addition of
PD098059 (50 mmol/L) simultaneously or at intervals
after exposure of SMCs to PDGF (5 ng/ml). Results are
expressed as mean percent of control (PDGF-stimulated)
chemotaxis ± SD. All experiments were repeated three
times using cells derived from different saphenous veins.
Representative examples are displayed.
mediates SMC proliferation is not surprising because
this signaling protein is known to be associated with
proliferation in numerous other cells. The role of
MAPK activation in migration is less well under-
stood.7-9 Our studies using a specific inhibitor of
MAPKK conclusively demonstrate that MAPK is
necessary for migration after stimulation of SMCs
with PDGF. However, these data do not establish
whether activation of MAPK alone is sufficient to
induce migration of human vascular SMCs.
Interestingly, stimulation of SMCs with the potent
growth factor bFGF produces a pattern of MAPK
activation that is almost identical to that induced by
PDGF.4 If induction of MAPK activity was by itself
sufficient to produce migration, it would therefore
be anticipated that bFGF, like PDGF, would be a
potent agonist of cell motility. However, we have
previously found that bFGF stimulates little or no
migration of human saphenous vein SMCs.18
Therefore, a very strong early peak in MAPK activi-
ty, such as that induced by bFGF, does not necessar-
ily result in SMC chemotaxis. It can be inferred from
these findings that other signaling pathways must be
activated in concert with MAPK for SMC migration
to occur.
The finding that MAPK activation is necessary
for both migration and proliferation raises the obvi-
ous dilemma of how one signaling protein can medi-
ate two very distinct processes. Previous studies with
MAPK in our laboratory revealed an association
between prolonged MAPK activation after growth
factor stimulation and the potential for the same
growth factors to stimulate SMC proliferation.4,5
For example, PDGF and bFGF are both potent ago-
nists of SMC proliferation and both growth factors
activate MAPK for periods up to 24 hours, whereas
angiotensin II, which does not stimulate SMC pro-
liferation, produces only an early peak in MAPK
activity. Our current studies provide additional sup-
port for the hypothesis that the timing of MAPK
activation determines its physiologic consequence.
By adding the inhibitor PD098059 at intervals after
stimulation of SMCs with PDGF, we were able to
isolate the portion of MAPK activity that mediated
both migration or proliferation. Inhibition of MAPK
at any point during the first 15 minutes after PDGF
stimulation either diminished or abolished SMC
chemotaxis, whereas inhibition of MAPK beyond 15
minutes had no effect on SMC migration. From
these findings, we can conclude that the early rise in
MAPK activity that peaks at approximately 10 min-
utes is responsible for SMC chemotaxis. More pro-
longed activation of MAPK was required for SMC
proliferation. Inhibition of MAPK at any point with-
in the first hour after PDGF stimulation eliminated
the SMC proliferative response, whereas the addi-
tion of the inhibitor after 4 hours had no effect.
Thus MAPK activation between 1 and 4 hours is
necessary for SMC proliferation.
In an interesting series of experiments, Duff and
Berk19 tested the hypothesis that prolonged activa-
tion of MAPK is associated with SMC proliferation.
These authors found, as did we, that stimulation of
SMCs with angiotensin II led to only a brief activa-
tion of MAPK and little SMC proliferation. By inac-
tivating the MAPK phosphatase, MAPK phos-
phatase-1, these investigators artificially produced a
situation in which stimulation of SMCs with
angiotensin resulted in persistent MAPK activation.
They predicted that cells treated in this manner
would have an increased propensity to proliferate.
However, the prolongation of MAPK activation that
resulted from the elimination of MAPK phos-
phatase-1 led to diminished survival of SMCs; in
fact, apoptosis was induced in these cells. These
observations, although surprising, may still be com-
patible with our finding that MAPK activity between
1 and 4 hours is necessary for SMC proliferation. It
is possible that a high level of MAPK activity sus-
tained beyond 4 hours, as was the case with their
model, is actually deleterious to SMCs.
The concept that temporal variations in MAPK
activity might mediate distinct cellular events has
been proposed by others. In the PC12 cell, the
bimodal activation of MAPK is also associated with
two distinct physiologic events. In contrast to our
findings with SMCs, the early phase of MAPK activ-
ity appears to mediate proliferation of PC12 cells,
and subsequent activity is associated with cell differ-
entiation.11 Susa et al.17 have also proposed that cel-
lular proliferation is dependent on late signaling
events. For example, the second of two phases of
protein kinase C activation, the phase stimulated by
phosphatidylcholine, is responsible for cellular pro-
liferation. Our data provide further support for the
hypothesis that the timing of a signaling event is an
important determinant of the subsequent cellular
response, as we have demonstrated an association
between early MAPK activation and SMC migration
and later MAPK activation and cellular proliferation.
Multiple substrates for MAPK have been identi-
fied, many of which may potentially facilitate a pro-
liferative cellular response. These include S6 kinase,
the EGF receptor, and the transcription factors c-
Myc, c-Jun, and c-Fos. The link between MAPK and
the cellular mechanisms that underlie migration is
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less clear. MAPK has been identified immunohisto-
chemically in focal adhesion complexes after plating
of fibroblasts onto various substrates implicating this
protein in cytoskeletal activities such as attachment
and migration.20 Also, MAPK can phosphorylate
and activate the calcium/calmodulin–dependent
protein kinase, myosin light chain kinase. Klemke et
al.7 have shown that MAPK may effect cell motility
in FG carcinoma and COS-7 cells by modulating
this protein and its subsequent effect on myosin.
Alternatively, Fox et al.21 have postulated that bFGF
may stimulate migration of endothelial cells through
MAPK-mediated production of PLA2 and arachi-
donic acid.
The upstream pathways that link growth factor
receptors such as the PDGF receptor to MAPK have
been better defined. Ligand attachment to the
PDGF receptor leads to tyrosine phosphorylation of
shc proteins inducing their association with the SH2
domain of the adapter protein Grb2. This protein
complex then targets the nucleotide exchange factor
SOS, which in turn associates with and activates the
GTP-binding protein p21ras. Ras activates the serine
threonine kinase raf, which triggers a protein kinase
cascade that leads to the activation of MAPK by the
dual specificity protein kinase, MAPKK, which phos-
phorylates MAPK on threonine and tyrosine
residues. The importance of upstream proteins such
as raf and ras in cellular proliferation has been estab-
lished. Although there appear to be multiple varia-
tions in the sequence of this upstream signaling cas-
cade, this pathway appears to universally facilitate
cellular proliferation in response to multiple growth
factors. The necessity of this same signaling pathway
for cell migration is less well established. Studies by
Sosnowski et al.22 and Fox et al.21 have demonstrat-
ed a role for ras in the migration of endothelial cells.
In these studies, injected oncogenic ras stimulated
migration, and either a neutralizing ras-specific anti-
body or a ras-dominant interfering mutant protein
inhibited migration. Kundra et al.23 studied the
importance of ras in the movement of SMCs and
found that inhibition of ras blocked SMC migration,
although surprisingly, overexpression of ras also
inhibited migration. It is clear from these studies
that p21ras, which is upstream from MAPK, is
involved in the signaling cascade that leads to migra-
tion, providing further support for our contention
that the activation of the MAPK pathway is critical
for SMC locomotion.
Recently, additional isotypes of MAPK have been
identified, including a 38kD protein, p38/RK, and
a 54 kd protein, SAPK/JNK.15 These proteins are
activated by inflammation, cytokines, and cellular
stresses rather than growth factors, and they appear
to have completely distinct, almost opposite, roles in
cellular function. In most nonlymphoid cells, these
two pathways function primarily to inhibit cell
growth and to promote either necrotic or apoptotic
cell death. It remains to be determined what role, if
any, these new isotypes might play in SMC function,
specifically proliferation and migration.
Accumulation of SMCs within the intima of the
injured artery is essential for the development of
intimal hyperplasia, and both SMC migration and
proliferation contribute to this process. The relative
importance of these two events is not clear; howev-
er, inhibition of both migration and proliferation
would provide a potent means for preventing the
development of hyperplastic lesions. We have
learned that MAPK is an essential intermediate in
the intracellular signaling pathways that mediate
both SMC migration and proliferation. Moreover,
different phases of MAPK activation are responsible
for these two distinct events. Although our findings
thus far are from in vitro studies, we believe that the
MAPK inhibitor, PD098059, could potentially be
used to selectively inhibit intimal hyperplasia and
control this process that so greatly limits the
longevity of vascular reconstructions.
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